Question · asked by 1 review
Modafinil vs placebo: Leaving the study early
- Population
- schizophrenia or related disorders
- Intervention
- Modafinil
- Comparison
- placebo
- Outcome
- Leaving the study early
Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Modafinil vs placebo Leaving the study early ‐ for any reason · schizophrenia or related disorders Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty). Modafinil for people with schizophrenia or related disorders (2019) · Cochrane Headline outcomes only | RR 1.26 [0.63, 2.53] | 9 studies · 357 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Modafinil for people with schizophrenia or related disorders 2019 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.